Using Magnetic Resonance Spectroscopy to Monitor Non-Hodgkin's Lymphoma Treatment
Author Information
Author(s): S.R. Smith, P.A. Martin, J.M. Davies, R.H.T. Edwards, A.N. Stevens
Primary Institution: University of Liverpool
Hypothesis
Can phosphorus magnetic resonance spectroscopy (MRS) detect biochemical changes in non-Hodgkin's lymphoma in response to chemotherapy?
Conclusion
Phosphorus MRS can detect early biochemical changes in non-Hodgkin's lymphoma that may indicate treatment response before any reduction in tumor size occurs.
Supporting Evidence
- Pre-treatment spectral characteristics differed between high and low grade lymphomas.
- A larger inorganic phosphate peak was observed in high grade lymphomas.
- Metabolite changes were detected before reductions in tumor size.
- Consistent changes in metabolite ratios were observed with treatment.
- The PDE/PATP ratio may serve as an early indicator of treatment response.
Takeaway
Doctors can use a special scan to see how cancer cells change when they get treatment, even before the tumors get smaller.
Methodology
Eight patients with non-Hodgkin's lymphoma underwent serial phosphorus MRS before and after chemotherapy to assess changes in metabolite ratios.
Potential Biases
Potential biases may arise from the small sample size and the specific patient demographics.
Limitations
The study is preliminary and involved a small sample size, which may limit the generalizability of the findings.
Participant Demographics
Patients included both males and females aged 32 to 78 with newly diagnosed non-Hodgkin's lymphoma.
Statistical Information
P-Value
0.018, 0.036
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website